Get access

Evidence for and Pathophysiologic Implications of Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Fibromyalgia and Chronic Fatigue Syndrome



    Corresponding author
    1. Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285 USA
      Additional correspondence information: Telephone: 317-277-2443; Fax: 317-277-9551; e-mail:
    Search for more papers by this author

    1. Department of Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 USA
    Search for more papers by this author

Additional correspondence information: Telephone: 317-277-2443; Fax: 317-277-9551; e-mail:


Abstract: Chronic fatigue syndrome (CFS) is characterized by profound fatigue anad an array of diffuse somatic symptoms. Our group has established that impaired activation of the hypothalamic-pituitary-adrenal (HPA) axis is an essential neuroendocrine feature of this condition. The relevance of this finding to the pathophysiology of CFS is supported by the observation that the onset and course of this illness is excerbated by physical and emotional stressors. It is also notable that this HPA dysregulation differs from that seen in melancholic depression, but shares features with other clinical syndromes (e.g., fibromyalgia). How the HPA axis dysfunction develops is unclear, though recent work suggests disturbances in serotonergic neurotransmission and alterations in the activity of AVP, an important co-secretagogue that, along with CRH, influences HPA axis function. In order to provide a more refined view of the nature of the HPA dusturbance in patients with CFS, we have studied the detailed, pulsatile characteristics of the HPA axis in a group of patients meeting the 1994 CDC case criteria for CFS. Results of that work are consistent with the view that patients with CFS have a reduction of HPA axis activity due, in part, to impaired central nervous system drive. These observations provide an important clue to the development of more effective treatment to this disabling condition.

Get access to the full text of this article